to compare the efficacy of drug-eluting bead transarterial chemoembolization combined with radiofrequency ablation (deb-tace rfa) versus deb-tace alone in chinese hepatocellular carcinoma (hcc) patients.
the 28 patients receiving deb-tace rfa and 74 hcc patients receiving deb-tace were recruited in this study. treatment responses, progression-free survival (pfs), and overall survival (os) were evaluated.
共纳入28例接受deb-tace rfa治疗和74例接受deb-tace（100-300μm callispheres微球加载盐酸表柔比星80mg）治疗的hcc患者。评估治疗反应、无进展生存期(pfs)和总生存期(os)。
one to 3 months after treatments, the proportion of patients achieving complete response (cr) (78.6% vs 33.8%, p<.001) and objective response rate (orr) (92.9% vs 78.4%, p=.010) were elevated in deb-tace rfa group compared with deb-tace group. multivariate logistic regression displayed that deb-tace rfa was an independently predicting factor for better cr(p=.006). subgroup analysis of cr achievement illuminated that deb-tace rfa disclosed better cr achievement in patients with history of cirrhosis (p<.001), tumor located in right liver (p=.003), bilobar disease (p=.013), tumor size <3.3cm (p=.001), no portal vein invasion (p=.001), no hepatic vein invasion (p<.001), child-pugh stage a (p<.001), barcelona clinic liver cancer (bclc) stage0, a-b (p<.001), abnormal alpha-fetoprotein (afp) (p=.001) and normal afp (p=.016). the pfss were similar between 2 groups(p=.112), however, the os was more prolonged in deb-tace rfa group (p=.025) compared with deb-tace group. and subgroup analysis displayed that pfs of patients with largest nodule size >3.3cm (p=.025) was longer and patients with unilobar disease (p=.009), and patients with no hepatic invasion (p=.019) and child-pugh stage a (p=.037) had more favorable os in deb-tace rfa group compared with deb-tace group.
治疗1 - 3个月后，deb-tace rfa组完全缓解率(cr) (78.6% vs. 33.8%, p<.001)、客观缓解率(orr) (92.9% vs. 78.4%, p=.010)显著高于deb-tace组。多元logistic回归分析显示，deb-tace rfa是较好cr的独立预测因素(p=.006)。有关cr的亚组分析显示，deb-tace rfa组取得较好的cr与患者肝硬化史 (p<.001)、肿瘤位于右肝叶(p = .003)、双叶疾病(p = .013)、肿瘤大小< 3.3cm (p=.001)、无门静脉侵犯(p=.001)、无肝静脉侵犯(p<.001)、child-pugh 分级a级(p<.001)、巴塞罗那肝癌分期(bclc)0，a-b期(p<.001)、异常afp (p=.001)以及正常范围afp (p=.016)有关。两组间pfss相似(p=.112)，然而，deb-tace rfa组os较deb-tace组显著延长(p=.025)。亚组分析显示，与deb-tace组相比，deb-tace rfa组中最大结节>3.3cm (p=.025)的患者pfs更长；deb-tace rfa组单叶性肝病(p=.009)、无肝静脉侵犯(p=.019)以及child-pugh a 级(p=.037)患者的os更长。
deb-tace rfa achieved better treatment responses and os compared with deb-tace alone in chinese hcc patients.